...
首页> 外文期刊>Cardiology >Hybrid Revascularization: A Review
【24h】

Hybrid Revascularization: A Review

机译:杂交血运重建:审查

获取原文
获取原文并翻译 | 示例

摘要

Hybrid coronary revascularization (HCR) combines surgical bypass with percutaneous coronary intervention (PCI) performed either during the same procedure or in a staged approach within 60 days. Coronary artery bypass grafting using the left internal mammary artery (LIMA) has shown excellent long-term patency with improved patient survival. It remains the gold standard treatment for the majority of patients with multivessel coronary artery disease. However, saphenous vein grafts have poor long-term patency. Advances in stent technology have resulted in reduced rates of thrombosis and restenosis, making PCI a viable alternative to coronary surgery in selected patients. HCR is attractive as a less invasive method of coronary revascularization which preserves the benefits of the LIMA performed with less invasive surgical techniques with the efficacy of newer generation stents. (C) 2018 S. Karger AG, Basel
机译:杂交冠状动脉血运重建(HCR)将手术旁路与经皮冠状动脉干预(PCI)相结合,在60天内或在分期的方法中进行。 使用左内部乳腺动脉(利马)冠状动脉旁路接枝显示出优异的长期通畅,具有改善的患者存活。 它仍然是大多数多型冠状动脉疾病患者的黄金标准治疗。 然而,隐静脉移植物具有差的长期通畅。 支架技术的进步导致血栓形成和再狭窄的速率降低,使PCI在选定患者中成为冠状动脉手术的可行替代品。 HCR作为冠状动脉血运重建的侵入方法具有吸引力,其保留了利用较少的外科手术技术进行了利用的益处,具有较新一辈支架的功效。 (c)2018年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号